Focus: Leadingtac is a Shanghai-based small molecule pharmaceutical company founded in 2019, currently in Series B stage with a portfolio heavily concentrated in generic and near-generic drugs across neurology, cardiovascular, and oncology indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Leadingtac Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Revenue anchor (65% of total) but already post-patent cliff; generic competition eroding margins.
Help build intelligence for Leadingtac Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Leadingtac Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Brand equivalent approaching loss of exclusivity; limited runway for differentiation or premium pricing.
Mature generic with minimal growth potential; routine maintenance-level revenue.
Commodity generic; no Part D revenue reported.
Oncology/hematology generic with established utility but no disclosed revenue traction.
3 discontinued, 1 duplicate formulations not shown
Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors - BioWorld News
Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors BioWorld News
Daewoong Pharmaceutical patents divulge new IRAK-4 inhibitors - bioworld.com
Daewoong Pharmaceutical patents divulge new IRAK-4 inhibitors bioworld.com
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+11 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo